Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 1766 results for patient safety

  1. Epiretinal brachytherapy for wet age-related macular degeneration (AMD) should only be used in the context of research. Research studies should address whether epiretinal brachytherapy reduces the progression of wet AMD and whether it can reduce the number of injections of antivascular endothelial growth factor agents (anti-VEGF) required. Long-term outcomes should be reported.

    degeneration (AMD) is inadequate and limited to small numbers of patients. With regard to safety, vitrectomy has...

    Research recommendation
    Published
    9 June 2015

  2. NICE encourages further research into endoscopic radiofrequency ablation for Barrett's oesophagus with no dysplasia. Studies should define clearly the policies used for histological diagnosis. Outcomes should include complete resolution of Barrett's oesophagus, change and progression to low-grade dysplasia, high-grade dysplasia or cancer. All complications should be reported, particularly development of strictures. Comparative studies against surveillance would be useful.

    explanatory notes(if applicable) Current evidence on the efficacy and safety of endoscopic radiofrequency ablation for Barrett's...

    Research recommendation
    Published
    9 June 2015

  3. NICE encourages further research into intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer. Research should include randomised controlled trials, which stratify patients by risk and give adequate follow-up. They should report frequency of adverse events, patientreported outcome measures, overall and disease-free survival and quality of life.

    cancer. Research should include randomised controlled trials, which stratify patients by risk and give adequate follow-up. They should...

    Research recommendation
    Published
    12 December 2018

  4. NICE encourages further research into the efficacy of MRI-guided transcutaneous focused ultrasound for uterine fibroids. Research studies should report long-term outcomes, including the need for further treatment. Data on the incidence and outcomes of subsequent pregnancy in patients who choose this procedure because they wish to maintain or improve their fertility are particularly important.

    treatment. Data on the incidence and outcomes of subsequent pregnancy in patients who choose this procedure because they wish to...

    Research recommendation
    Published
    9 June 2015

  5. NICE encourages further research into transcranial direct current stimulation (tDCS) for depression, which should document how patients were selected and any other treatments they were having. It should describe the precise method and regime used for administering tDCS. Outcome measures should include the duration of effect. NICE may update the guidance on publication of further evidence.

    direct current stimulation (tDCS) for depression, which should document how patients were selected and any other treatments they were...

    Research recommendation
    Published
    12 October 2015

  6. What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

    Recommendation ID NG191/3 Question What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs)...

    Research recommendation
    Published
    10 August 2021

  7. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    Recommendation ID NG191/2 Question What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE)...

    Research recommendation
    Published
    10 August 2021

  8. Service user experience in adult mental health services (QS14)

    This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    31 July 2019
    View quality statements

    Sections for QS14

  9. Long-term effects of IVF with or without intracytoplasmic sperm injection in children:- What are the long-term (over 20 years) effects of IVF with or without intracytoplasmic sperm injection (ICSI) in children in the UK?

    topic is important in informing patients, service providers and society at large about the potential long-term safety of...

    Research recommendation
    Published
    9 June 2015

  10. Access to medicines:- Does the use of directly observed supply of named high-risk medicines (that is, not supplying the medicines to people to hold in-possession), reduce diversion, abuse and non-adherence?

    observed administration is reserved for high-risk medicines and vulnerable patients. But different medicines are categorised as high...

    Research recommendation
    Published
    10 February 2017

  11. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    Recommendation ID NG191/1 Question What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological...

    Research recommendation
    Published
    10 August 2021

  12. What are the appropriate indications, effectiveness and safety of LDL apheresis in people with heterozygous FH?

    Question What are the appropriate indications, effectiveness and safety of LDL apheresis in people with heterozygous FH? Any explanatory

    Research recommendation
    Published
    15 November 2019

  13. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued

  14. Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

    Discontinued Reference number: GID-TA10105

    Technology appraisal guidance
    Discontinued

  15. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

    Technology appraisal guidance
    Discontinued